Ozempic tablets replace Rybelsus at US pharmacies

Novo Nordisk's oral semaglutide arrived at US pharmacies on May 4, 2026 under a different name and a new set of doses. The tablets now ship as Ozempic in 1.5 mg, 4 mg and 9 mg strengths, and the Rybelsus brand — the label this medicine has carried in the US since its 2019 approval — is being retired ^[2][3][5].

The change is more than cosmetic. Novo Nordisk shrank the pill and gave it a new coating. Michael Radin, the company's executive director of diabetes medical affairs, said the rework raised bioavailability, so a smaller amount of semaglutide per tablet delivers results equivalent to the older product ^[5]. Under that mapping, Rybelsus 3 mg, 7 mg and 14 mg line up with Ozempic tablets 1.5 mg, 4 mg and 9 mg ^[5]. Novo Nordisk describes efficacy and safety as unchanged, and MPR reported the same ^[3][4]. The FDA cleared the reformulated version on January 30, 2026, following a bioequivalence study and a clinical trial program ^[2][4].

The transition is not milligram for milligram. As MPR told clinicians, the old and new strengths do not swap one to one, so a pharmacy cannot simply relabel an existing prescription ^[4]. Novo Nordisk's guidance to people already taking Rybelsus is to keep using it as directed and raise the change with a health care professional ^[3][4][5]. Shipments of Rybelsus to US wholesalers are ending, though the brand remains on sale in other countries ^[3][5].

Both versions treat type 2 diabetes. Ozempic tablets are cleared, along with diet and exercise, to improve blood sugar in adults and to cut the risk of major cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes who face high risk of them ^[2][4]. Novo Nordisk calls it the only oral GLP-1 approved for both primary and secondary cardiovascular risk reduction in that group ^[3]. Dosing is once a day in the morning on an empty stomach, and the tablets are not approved for children ^[2][3].

Pricing divides by how people pay. Novo Nordisk says most insured patients with type 2 diabetes will owe as little as $25 for up to a three-month prescription. Cash customers going through NovoCare Pharmacy or certain telehealth providers are quoted $149 for the 1.5 mg starting dose, $199 a month at 4 mg and $299 a month at 9 mg, with one 30-tablet bottle counted as a month; government beneficiaries are excluded and eligibility limits apply ^[3][4]. The tablets are reaching more than 70,000 pharmacies, and the company makes them start to finish in the US, mainly at North Carolina sites ^[3][5].

Like other semaglutide products, the tablets carry a boxed warning about thyroid C-cell tumors found in rodents, plus warnings covering pancreatitis, vision changes, low blood sugar, kidney injury from dehydration, severe stomach reactions, allergic reactions and gallbladder disease. Nausea, vomiting, diarrhea, stomach pain, constipation and reduced appetite are the most commonly reported side effects ^[2][3].

Why it matters for patients

Anyone who takes oral semaglutide in the US faces a paperwork change even though the molecule stays the same. A prescription written for one of the three Rybelsus strengths will not match a standard Ozempic tablet strength, so a new order naming the Ozempic product and its dose is required ^[4][5]. Novo Nordisk's stated advice is to continue the current supply as directed and discuss timing with a prescriber rather than stopping or switching alone ^[3][4][5].

The shared Ozempic name also leaves room for confusion. The brand now covers a weekly injection and a daily pill, and the two are approved for different things: the injection additionally includes reducing the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, while the tablets do not ^[2][3].

Cost remains individual. The advertised $25 applies to most, not all, insured patients with type 2 diabetes, and out-of-pocket prices climb with the dose ^[3][4]. How particular commercial plans and pharmacy benefit managers will classify the newly branded pill has not been disclosed.

Supply is one area Novo Nordisk has addressed directly. Jamey Millar, the company's executive vice president of US operations, said it is confident about reliably supplying both the Ozempic pill and the Wegovy pill in the US ^[5].

What happens next

Novo Nordisk has filed a supplemental application for a 25 mg Ozempic tablet in adults with type 2 diabetes and expects an FDA decision before the end of 2026 ^[3]. Outside the US, the Rybelsus name stays in place ^[3][5].